Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Joshua Bumgardner

Physician Assistant Centerville, OH Physician Assistant

NPI 1861894958 CMS profile 10779652

7700 Washington Village Dr Ste 210, Centerville, OH 45459

Open in the dashboard

General payments

$6,927

18 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Joshua Bumgardner of Centerville, OH is reported in the CMS Open Payments database as having received $6,927 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $40 2
2023 General $31 2
2022 General $363 5
2021 General $6,493 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Bumgardner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Joshua Bumgardner were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Joshua Bumgardner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $6,493 $132 $37–$438 $132
2022 $363 $155 $48–$522 $149
2023 $31 $167 $52–$557 $160
2024 $40 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Amgen Inc. $6,556 13 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $205 2 payments
  3. Stryker Corporation $125 1 payment
  4. Tempus AI, Inc $40 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,063 5 payments
  2. Food and Beverage $865 13 payments
Products named General payments · program years 2021–2024
  1. AIMOVIG $6,412 8 payments
  2. Kerendia $205 2 payments
  3. Repatha $144 5 payments
  4. AUGMENT INJECTABLE $125 1 payment
  5. Otezla $45 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 105 drugs

Part D claims

4,052

Median for Physician Assistant: 241

Drug cost

$310,607

Median for Physician Assistant: $4,110

Branded share of claims

20%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 35 $44,551
Trulicity Dulaglutide Brand 28 $42,144
Repatha Sureclick Evolocumab Brand 23 $38,717
Ozempic Semaglutide Brand 28 $34,509
Tresiba Flextouch U-200 Insulin Degludec Brand 22 $22,011
Eliquis Apixaban Brand 18 $17,252
Linzess Linaclotide Brand 20 $15,634
Praluent Pen Alirocumab Brand 11 $14,047
Farxiga Dapagliflozin Propanediol Brand 17 $11,679
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $10,864

The 10 drugs with the highest cost, of 105 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$25,501

Of which drugs: $3,284

Medicare patients

201

Average age 71

Services billed

1,118

113 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Depression 26%
Diabetes 24%
Ischemic heart disease 22%
Chronic kidney disease 21%
Atrial fibrillation 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 80 $61

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record